Meeting Overview | We are pleased to invite you to the Expert PracticeSM in Hematology meeting in Dubrovnik, Croatia, on 16-17 September 2011.
During this case-based meeting, leaders in the field will discuss, in an interactive format, clinical issues encountered daily by practicing physicians.
This meeting is restricted to healthcare professionals based outside of the United States. You will be asked to provide your credentials to register.
For available travel grants, please contact travelgrants@prIMEoncology.org
|
Location | Radisson Blu
Na Moru 1
20234 Orašac
Dubrovnik, Croatia
|
Target Audience | This educational activity is designed for hematologists, oncologists, and other healthcare providers involved and/or interested in the management of patients with hematologic malignancies.
|
Learning Objectives | After successful completion of this educational activity, participants should be able to:
-
Summarize treatment options and strategies for the management of myelodysplastic syndromes
-
Evaluate the use of prognostic markers to guide the therapeutic decision-making process in patients with chronic lymphocytic leukemia
-
Assess currently available and emerging treatment options for multiple myeloma
-
Summarize treatment options for patients with newly diagnosed and resistant/refractory chronic myelogenous leukemia
-
Discuss methodologies to properly diagnose and manage patients with lymphomas
|
 Proposed Faculty | Chairman
Aristoteles Giagounidis, MD, PhD
St Johannes Hospital
Duisburg, Germany
Faculty
Alexander Egle, MD
University Hospital Salzburg
Salzburg, Austria
|
Juan Luis Steegmann, MD, PhD
Hospital Universitario de la Princesa
Madrid Spain
|
Roman Hájek, MD
Masaryk University
Brno, Czech Republic
|
Marek Trneny, MD, PhD
Charles University Hospital
Prague, Czech Republic
|
Eduardo Olavarria, MD
Hospital De Navarra
Pamplona, Spain
|
Luciano Wannesson, MD
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
|
|
|
|
|
Agenda | Day 1—Friday 16 September
| 15.45 |
Welcome, introduction, and demographic questions
Aristoteles Giagounidis, MD, PhD
|
| 16.05 |
Case #1—Low-risk myelodysplastic syndromes with del (5q) chromosomal aberration
Aristoteles Giagounidis, MD, PhD
|
| 16.40 |
Case #2—Multiple myeloma (MM): Treatment of the transplant eligible patient
Roman Hájek, MD
|
| 17.15 |
Break
|
| 17.35 |
Case #3—Relapsed/refractory MM: Advances in treatment
Roman Hájek, MD
|
| 18.10 |
Case #4—Chronic lymphocytic leukemia: New advances in research and treatment
Alexander Egle, MD
|
| 18.45 |
Closing Remarks |
Day 2—Saturday 17 September
| 09.30 |
Welcome and introduction
Aristoteles Giagounidis, MD, PhD
|
| 09.40 |
Case #5—Follicular lymphoma
Luciano Wannesson, MD
|
| 10.15 |
Case #6—Evolving standards of care for newly diagnosed chronic myelogenous leukemia (CML)
Eduardo Olavarria, MD
|
| 10.50 |
Break
|
| 11.10 |
Case #7—Second-line treatment of CML: Selecting the appropriate therapy
Juan Luis Steegmann, MD, PhD
|
| 11.45 |
Case #8—Relapsed/refractory mantle-cell lymphoma: Novel approaches for patient management
Marek Trneny, MD, PhD
|
| 12.20 |
Concluding remarks |
|
|
|
|
Downloadable Slides | Case #1—Low-risk myelodysplastic syndromes with del (5q) chromosomal aberration
Aristoteles Giagounidis, MD, PhD
Case #2—Multiple myeloma (MM): Treatment of the transplant eligible patient
Roman Hájek, MD
Case #3—Relapsed/refractory MM: Advances in treatment
Roman Hájek, MD
Case #4—Chronic lymphocytic leukemia: New advances in research and treatment
Alexander Egle, MD
Case #5—Follicular lymphoma
Luciano Wannesson, MD
Case #6—Evolving standards of care for newly diagnosed chronic myelogenous leukemia (CML)
Eduardo Olavarria, MD
Case #7—Second-line treatment of CML: Selecting the appropriate therapy
Juan Luis Steegmann, MD, PhD
Case #8—Relapsed/refractory mantle-cell lymphoma: Novel approaches for patient management
Marek Trneny, MD, PhD |
Organizer | This meeting is a prIME Oncology activity.
|
Accreditation | This activity has received accreditation approval by the Accreditation Council of Oncology in Europe (ACOE) and is granted with 5 European CME credits.
Expert Practice in Hematologic MalignanciesSM in Dubrovknik, Croatia on 16-17 September 2011 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.
Expert Practice in Hematologic MalignanciesSM is designated for a maximum of 6 European CME credits (ECMECs).
|
Support | Support for this educational activity is provided by Bristol-Myers Squibb and Celgene Corporation.
|
|
